Author

Y. Patil

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Organism:human· 3 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:clustering· 1 Assay:DNA methylation· 1

Frequent Co-Authors

A. Sadanandam· 3 shared C. Ragulan· 2 shared D. Cunningham· 2 shared A. Bryant· 1 shared A. Furness· 1 shared A. Korlimarla· 1 shared A. Mathew· 1 shared A. Woolston· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Sadanandam

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A comprehensive analysis of immune landscape of Indian triple negative breast cancer

A. Korlimarla, H. PS, J. Prabhu, C. Ragulan, Y. Patil, S. VP, K. Desai, A. Mathew, S. Appachu, R. Diwakar, S. BS, M. Cheang, A. Sadanandam

This study identifies three immune subtypes in Indian triple-negative breast cancer patients, showing similarities to Western TNBCs and potential for immunotherapy response.

bioRxiv · Mar 6, 2022 · PreprintCancer Biology

Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer Samples into Molecular Subtypes

C. Ragulan, K. Eason, G. Nyamundanda, Y. Patil, P. Poudel, E. Fontana, M. Del Rio, S.-L. Koo, W. S. Tan, P. Martineau, D. Cunningham, I. Tan, A. Sadanandam

The paper validates a NanoString-based biomarker assay for classifying colorectal cancer samples into molecular subtypes with high concordance across platforms and tissue types.

Scientific Reports · May 21, 2019Peer-reviewedCancer Biology

Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer

A. Woolston, K. Khan, G. Spain, L. J. Barber, B. Griffiths, R. Gonzalez Exposito, Y. Patil, S. Mansukhani, M. N. Davies, A. Furness, F. Sclafani, C. Peckitt, K. Kouvelakis, R. Ranftl, R. Begum, , M. Gerlinger

The paper analyzes genomic and transcriptomic data from CRC patients treated with cetuximab to identify resistance mechanisms and immune landscape changes during anti-EGFR therapy.

bioRxiv · Oct 19, 2018Cancer Biology